GLP-1 Supply Status Australia 2026: Ozempic, Wegovy, Mounjaro, Saxenda Availability

As at May 2026, GLP-1 supply has substantially improved compared to 2023-2024. Ozempic 0.5mg, 1.0mg, 2.0mg, all Wegovy doses, all Mounjaro doses, and Saxenda are broadly available. Sporadic issues remain with Ozempic 0.25mg (starter dose) in some regional pharmacies. Patients starting GLP-1 should phone ahead to confirm stock before booking GP appointment.

A combination of: (1) Global demand surge driven by viral social media + celebrity endorsements, (2) limited global manufacturing capacity (Novo Nordisk only has so many production lines for semaglutide), (3) off-label prescribing for weight loss substantially expanding the user base beyond T2D patients, (4) Australian TGA + PBS authority demand spiking ahead of supply forecasts. Novo Nordisk has since expanded capacity in Denmark + United States; supply normalised in late 2025.

Call ahead. The TGA Therapeutic Goods Administration Medicine Shortages page (tga.gov.au/medicine-shortages-information-initiative) publishes formal shortage notifications but lags real-world stock by weeks. Pharmacist Society of Australia maintains a more current network — call your local pharmacy + ask "do you have Ozempic 1.0mg in stock for a script that comes in tomorrow?" Most pharmacists know within minutes.

In Australia, no — for now. TGA + AHPRA have clamped down on compounded semaglutide + tirzepatide since 2024. The relevant Schedule 4 (Prescription Only) status, combined with safety concerns about off-label compounding without sterility + dose accuracy controls, has made this pathway largely shut. If a pharmacy or telehealth service offers "compounded GLP-1", verify they\'re using approved branded medication, not compounded copy.

Step 1: phone several pharmacies in your area before assuming it\'s a generalised shortage. Step 2: ask your GP about temporary alternative doses. For Ozempic, dropping back from 1.0mg to 0.5mg for 4-8 weeks is medically reasonable (you\'ll lose some weight benefit but maintain glucose control). Step 3: consider switching to Wegovy (semaglutide same molecule, different brand pens) — typically same supply chain status. Step 4: as last resort, switch to Mounjaro (tirzepatide) with washout — but the cost may jump.

TGA + Department of Health do prioritise PBS-funded Ozempic for T2D patients during severe shortages. In 2023, the TGA issued formal guidance directing pharmacists to prioritise T2D patients with documented PBS Authority over off-label weight-loss patients. This guidance was largely informal in 2024-2025 as supply normalised. If supply tightens again, expect T2D patients to be prioritised.

No. Multi-month stockpiling is medically unsound (storage requirements + expiry dates) and contributes to shortages for other patients. Buy your next month\'s supply when you start using your current pen. If you have stable supply, no need to game the system. PBS prescriptions are valid for 12 months but you can only fill one month at a time.

Possibly. Two scenarios could trigger renewed shortages: (1) If PBS criteria expand to include weight-loss indication (currently flagged for 2026-27 review), demand spike could outpace supply. (2) If a new entrant takes share (oral semaglutide, retatrutide, future agonists), global capacity gets reallocated. Manufacturers signal increasing supply through 2026-27, but a sudden demand surge could trigger 3-6 month shortages again. Monitor TGA notifications.